According to a recent LinkedIn post from Truveta, the company’s Truveta Research unit has been cited in The Washington Post in connection with analysis of oral GLP-1 therapies. The post highlights internal findings that more than 36% of patients prescribed oral semaglutide (Wegovy pill) had not previously used a GLP-1 medication, suggesting incremental rather than purely switch-driven demand.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that oral GLP-1 options may help expand access to obesity and diabetes treatments across broader patient groups, and underscores the role of real-world data in tracking how new therapies are adopted. For investors, this visibility may point to Truveta’s growing relevance as an evidence-generation partner for pharma and healthcare stakeholders, potentially enhancing its competitive position in the real-world data and analytics market as GLP-1 usage scales.